Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram‐negative bacterial infections
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01095-25 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Yuanhao Wu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Huashan Hospital Affiliated to Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Renal Dialysis, Anti-Bacterial Agents, Cephalosporins, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
HRS-8427, a development-stage siderophore cephalosporin antibiotic, is being investigated for the treatment of aerobic Gram-negative bacterial infections, encompassing urinary tract infections and pulmonary infections. Participants with these indications frequently exhibit concomitant renal impairment (RI). Data from clinical studies suggest that ~60% to ~70% of unchanged HRS-8427 is excreted renally. A phase 1, multicenter, open-label study evaluated the effects of RI on the pharmacokinetics and safety of HRS-8427. In sub-study 1, 21 participants with mild to severe RI who were not on dialysis and six participants with normal renal function received single doses of 1,000 mg HRS-8427. In sub-study 2, six participants with end-stage renal disease (ESRD) requiring hemodialysis (HD) received single doses of the 1,000 mg HRS-8427 under dialysis and non-dialysis conditions, respectively. Plasma HRS-8427 area under the concentration-time curve from zero to infinity (AUC 0–∞ ) was ~1.2-fold, ~1.4-fold, 2.0-fold, and ~2.0-fold higher, respectively, in participants with mild, moderate, severe RI, and ESRD (without HD) relative to healthy controls. In dialysis-dependent subjects, the systemic exposure of HRS-8427 when dosed before HD was equivalent to 50.6% of that when dosed after HD. Adverse events (AEs) were mostly mild, and RI did not appear to be associated with an increased risk of AEs. CLINICAL TRIALS This study is registered with http://www.chinadrugtrials.org.cn/ as CTR20230658 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huashan Hospital Affiliated to Fudan University, Shanghai, China.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
- The First Hospital of Lanzhou University, Lanzhou, China.
- The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
- The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- The Central Hospital of Wuhan, Wuhan, China.
ORCID-Profile: Qiwen Han, Tengrui Yin, Yuanyuan Huang, Jing Zhang
Zitieren
APA
Wu, Y., Han, Q., Yang, H., Xue, J., Wang, L., Mao, X., Yin, T., Jiang, H., Xu, S., Huang, Y., Wang, T., He, Y., Luo, Y., Chen, W., & Zhang, J. (2026). Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram‐negative bacterial infections. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01095-25
Vancouver
Wu Y, Han Q, Yang H, Xue J, Wang L, Mao X, et al. Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram‐negative bacterial infections. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01095-25
BibTeX
@article{Wu2026,
author = {Wu, Yuanhao and Han, Qiwen and Yang, Haijing and Xue, Jun and Wang, Lili and Mao, Xiaomeng and Yin, Tengrui and Jiang, Hao and Xu, Sheng and Huang, Yuanyuan and Wang, Ting and He, Yan and Luo, Yuanyuan and Chen, Wenli and Zhang, Jing},
title = {Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram‐negative bacterial infections},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01095-25}
}
EUVIMED